表紙
市場調查報告書

CAR-T細胞療法市場:地區,目標抗原,臨床試驗/研究,各企業的世界預測

CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies

出版商 Renub Research 商品編碼 941638
出版日期 內容資訊 英文 167 Pages
商品交期: 最快1-2個工作天內
價格
CAR-T細胞療法市場:地區,目標抗原,臨床試驗/研究,各企業的世界預測 CAR T Cell Therapy Market Global Forecast by Regions, Targeted Antigens, Clinical Trials/Study, Companies
出版日期: 2020年06月01日內容資訊: 英文 167 Pages
簡介

全球CAR-T細胞療法市場在2028年將達到74億美元。市場成長的主要因素有促進成人及兒童的癌症的增加,推動癌症細胞療法研究的政策措施的增加以及全球範圍內臨床試驗的增加。

本報告提供全球CAR-T細胞療法市場的相關調查,提供市場成長要素和課題,全球法規,標的抗原·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 摘要整理

第2章 全球市場

第3章 市場佔有率

  • 各地區
  • 各標的抗原

第4章 標的抗原市場

  • CD19
  • CD20
  • GD2
  • CD22
  • CD30
  • CD33
  • HER2
  • Mesothelin (MESO)
  • EGFRvIII
  • 其他

第5章 各地區CAR-T細胞療法市場

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第6章 全球CAR-T細胞臨床試驗/研究

  • CD19
  • CD20
  • CD22
  • CD30
  • CD33
  • EGFRvIII
  • GD2
  • HER1
  • HER2
  • MESO

第7章 中國的CAR-T細胞臨床試驗詳細內容

  • 各都市
  • CD19
  • CD19以外
  • 固態腫瘤的CAR-T細胞

第8章 SWOT分析

第9章 法規

  • 美國
  • 歐洲聯盟
  • 中國

第10章 IPO /投資/資金籌措/聯盟

  • 創業投資投資
  • CAR-T企業的首次股票公開發行
  • CAR-T企業的策略性聯盟/交易
  • CAR-T技術信息

第11章 成長要素

  • CAR-T療法的FDA核准
  • 全球CAR-T細胞檢驗數的戲劇性增加

第12章 市場課題

  • 法規上的課題
  • 非常高價的CAR-T治療

第13章 Novartis

第14章 Gilead Sciences (Kite Pharma)

第15章 Celgene Corporation(Juno Therapeutics)

第16章 Celyad

目錄

For many years, the support of cancer therapy was chemotherapy, surgery and radiation therapy. However, in recent times, CAR-T cell therapy has been introduced as an incredibly supportive treatment for cancer patients. Since the introduction of chemotherapy, this treatment is one of the most significant breakthroughs. In this therapy, immune cells are collected from patients, and it is modified in the laboratory by doctors. After modification, these immune cells are infused back into the patient as they can easily recognize and kill cancer cells. These infused cells get multiplied and stay in the body as "living drugs." According to Renub Research analysis, CAR-T Cell Therapy Market is expected to be USD 7.4 Billion by the end of the year 2028.

Growth Factors for CAR-T Cell Therapy

Factors such as growing numbers of cancer in adults and children, and increasing policy initiatives to encourage cell therapy research in cancer, and increasing numbers of clinical trials worldwide are some of the main drivers for the global demand for CAR T cell therapy. The economic scenario in the CAR-T cell therapy industry is very dynamic, and key players compete with each other to gain access to major markets in the United States and Europe. Companies are seeking to secure treatment facilities to increase access for patients to their treatments.

Developments did by Companies in CAR T Cell Therapy

In 2017, a new milestone was set for oncology patients when the FDA approved the first two CD19-targeted known as (Chimeric Antigen Receptor) CAR T cell therapies produced by Novartis and Gilead Sciences known as Kite Pharma in the United States. Such two approvals have helped to improve the global demand for CAR T cell therapy because more companies are searching for this excellent opportunity to reach the marketplace. More than 200 CAR T clinical trials are ongoing or completed in various parts of the world. In 2018, Novartis announced its 33 approved centres in the U.S. and Gilead announced its 28 approved centres for the care of patients. Companies are also coming up with new developments in the field.

Celgene, a global company, is expected to file for approval in USFDA of bb2121 (idecabtagene vicleucel) in myeloma during the first half of 2020 and lisocabtagene maraleucel in lymphoma in the fourth quarter of 2020.

Renub Research latest study report "CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others), Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33, HER1, HER2, MESO, EGFRvII), Companies (Novartis, Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad)" provides a detailed and comprehensive insight of the global CAR T cell therapy market.

By Antigens - Based on antigens, CAR T Cell Therapy Market is further Segmented into 10 Segments

  • 1. CD19
  • 2. CD20
  • 3. GD2
  • 4. CD22
  • 5. CD30
  • 6. CD33
  • 7. HER2
  • 8. MESO
  • 9. EGFRvII
  • 10. Others

By Region - 6 Regions CAR T Cell Market is studied in this report

  • 1. North America
  • 2. Europe
  • 3. Asia Pacific
  • 4. Latin America
  • 5. Middle East
  • 6. Africa

All the companies have been studied from three points

  • Overview
  • Initiatives & Recent Developments
  • Revenue

Key Companies covered in this report are

  • Novartis
  • Gilead Sciences (Kite Pharma)
  • Celgene Corporation (Juno Therapeutics)
  • Celyad

Global - CAR T Cell Therapy Clinical Trials/Study

  • 1. CD19
  • 2. CD20
  • 3. GD2
  • 4. CD22
  • 5. CD30
  • 6. CD33
  • 7. HER1
  • 8. HER2
  • 9. MESO
  • 10. EGFRvII

China CAR T Cells Clinical Trials Details

  • By Cities CAR T Cells Clinical Trials
  • CD19 Directed CAR T Cells Clinical Trials
  • Non-CD19 Directed CAR T Cells Clinical Trials
  • Solid Tumors CAR T Cells Clinical Trials

Regulation of CAR T Cell Therapy in 3 Regions is covered in the report

  • United States
  • European Union
  • China

IPO/Investment/Funding/Partnership in CAR T Cell Therapy Market

  • Venture Capital Investment
  • Initial Public Offerings
  • Strategic Partnerships/Deals
  • Key CAR T Technology Deals

Table of Contents

1. Executive Summary

2. Global Chimeric Antigen Receptor (CAR)-T cell Therapy Market

3. Market Share - CAR-T Cell Therapy

  • 3.1 By Geographical Region
  • 3.2 By Targeted Antigens

4. Targeted Antigen Market

  • 4.1 CD19
    • 4.1.1 Introduction
    • 4.1.2 Market Size and Forecast
  • 4.2 CD20
    • 4.2.1 Introduction
    • 4.2.2 Market Size and Forecast
  • 4.3 GD2
    • 4.3.1 Introduction
    • 4.3.2 Market Size and Forecast
  • 4.4 CD22
    • 4.4.1 Introduction
    • 4.4.2 Market Size and Forecast
  • 4.5 CD30
    • 4.5.1 Introduction
    • 4.5.2 Market Size and Forecast
  • 4.6 CD33
    • 4.6.1 Introduction
    • 4.6.2 Market Size and Forecast
  • 4.7 HER2
    • 4.7.1 Introduction
    • 4.7.2 Market Size and Forecast
  • 4.8 Mesothelin (MESO)
    • 4.8.1 Introduction
    • 4.8.2 Market Size and Forecast
  • 4.9 EGFRvIII
    • 4.9.1 Introduction
    • 4.9.2 Market Size and Forecast
  • 4.10 Others
    • 4.10.1 Market Size and Forecast

5. Geographical CAR-T Cell Therapy Market (2016 -2026)

  • 5.1 North America
  • 5.2 Europe
  • 5.3 Asia Pacific
  • 5.4 Latin America
  • 5.5 Middle East
  • 5.6 Africa

6. Global - CAR-T Cell Clinical Trials/Study

  • 6.1 CD19
  • 6.2 CD20
  • 6.3 CD22
  • 6.4 CD30
  • 6.5 CD33
  • 6.6 EGFRvIII
  • 6.7 GD2
  • 6.8 HER1
  • 6.9 HER2
  • 6.10 MESO

7. China CAR-T Cells Clinical Trials Details

  • 7.1 By Cities CAR-T Cells Clinical Trials
  • 7.2 CD19 Directed CAR-T Cells Clinical Trials
  • 7.3 Non-CD19 Directed CAR-T Cells Clinical Trials
  • 7.4 Solid Tumors CAR-T Cells Clinical Trials

8. CAR-T Cell Therapy SWOT Analysis

  • 8.1 Strength
  • 8.2 Weakness
  • 8.3 Opportunities
  • 8.4 Threats

9. Regulation in CAR-T Cell Therapy

  • 9.1 United States
  • 9.2 European Union
  • 9.3 China

10. IPO/Investment/Funding/Partnership in CAR-T Cell Therapy Market

  • 10.1 Venture Capital Investment
  • 10.2 Initial Public Offerings of CAR-T Companies
  • 10.3 CAR-T Companies Strategic Partnerships/Deals
  • 10.4 Key CAR-T Technology Deals

11. Growth Drivers

  • 11.1 FDA Approvals of CAR-T Therapy
  • 11.2 Dramatically Increasing Number of CAR-T Cell Trials Globally

12. Challenges

  • 12.1 Regulatory Challenges
  • 12.2 Very Expensive CAR-T Therapy Treatment

13. Novartis

  • 13.1 Company Overview
  • 13.2 Initiatives
    • 13.2.1 Point 1
    • 13.2.2 Point 2 Kymriah® (tisagenlecleucel), First-in-class CAR-T Therapy from Novartis Received Second FDA Approval
    • 13.2.3 Point 2
  • 13.3 Financial Insight

14. Gilead Sciences (Kite Pharma)

  • 14.1 Company Overview
  • 14.2 Company Initiatives
    • 14.2.1 Point 1
    • 14.2.2 Point 2
  • 14.3 Company Financial Insight

15. Celgene Corporation (Juno Therapeutics)

  • 15.1 Company Overview
  • 15.2 Company Initiatives
    • 15.2.1 Point 1
    • 15.2.2 Point 2
  • 15.3 Company Financial Insight

16. Celyad

  • 16.1 Company Overview
  • 16.2 Company Initiatives
    • 16.2.1 Point 1
    • 16.2.2 Point 2
    • 16.2.3 Point 3
  • 16.3 Financial Insight

List of Figures

  • Figure 2-1: Global - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 2-2: Global - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 3-1: Global - CAR-T Cell Therapy Regional Market Share (Percent), 2017 - 2019
  • Figure 3-2: Global - Forecast for CAR-T Cell Therapy Regional Market Share (Percent), 2020 - 2028
  • Figure 4-1: Global - CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 4-2: Global - CD19 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-3: Global - Forecast for CD20 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-4: Global - Forecast for GD2 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-5: Global - Forecast for CD22 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-6: Global - Forecast for CD30 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-7: Global - Forecast for CD33 Antigen CAR-T Cell Therapy Market (Million US$), 2017 - 2028
  • Figure 4-8: Global - Forecast for HER2 Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-9: Global - Forecast for MESO Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-10: Global - Forecast for EGFRvIII Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 4-11: Global - Forecast for Others Antigen CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-1: North America - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-2: North America - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-3: Europe - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-4: Europe - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-5: Asia Pacific - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-6: Asia Pacific - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-7: Latin America - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-8: Latin America - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-9: Middle East - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-10: Middle East - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 5-11: Africa - CAR-T Cell Therapy Market (Million US$), 2017 - 2019
  • Figure 5-12: Africa - Forecast for CAR-T Cell Therapy Market (Million US$), 2020 - 2028
  • Figure 7-1: China - By Cities CAR-T Cells Clinical Trials (Number), 2017
  • Figure 11-1: Global - CAR-T New & Total Clinical Trials (Number), 2012-2017
  • Figure 11-2: Global - By Phase CAR-T Clinical Trials (Number), 2017
  • Figure 13-1: Novartis - Global Sales (Million US$), 2015 - 2019
  • Figure 13-2: Novartis - Forecast for Global Sales (Million US$), 2020 - 2028
  • Figure 14-1: Gilead Sciences - Global Sales (Million US$), 2017 - 2019
  • Figure 14-2: Gilead Sciences - Forecast for Global Sales (Million US$), 2020 - 2028
  • Figure 15-1: Celgene - Global Sales (Million US$), 2013 - 2019
  • Figure 15-2: Celgene - Forecast for Global Sales (Million US$), 2020 - 2028
  • Figure 16-1: Celyad - Global Sales (Million US$), 2013 - 2019
  • Figure 16-2: Celyad - Forecast for Global Sales (Million US$), 2020 - 2028

List of Tables

  • Table 3 1: Global - Current & Forecast for CAR-T Cell Therapy Targeted Antigens Market Share (Percent), 2017 - 2028
  • Table 6 1: Global - Details of CD19 CAR-T Studies, 2018
  • Table 6 2: Global - Details of CD20 CAR-T Studies, 2018
  • Table 6 3: Global - Details of CD22 CAR-T Studies, 2018
  • Table 6 4: Global - Details of CD30 CAR-T Studies, 2018
  • Table 6 5: Global - Details of CD33 CAR-T Studies, 2018
  • Table 6 6: Global - Details of EGFRvIII CAR-T Studies, 2018
  • Table 6 7: Global - Details of GD2 CAR-T Studies, 2018
  • Table 6 8: Global - Details of HER1 CAR-T Studies, 2018
  • Table 6 9: Global - Details of HER2 CAR-T Studies, 2018
  • Table 6 10: Global - Details of MESO CAR-T Studies, 2018
  • Table 7 1: China - CD19 Directed CAR-T Cells Clinical Trials, 2017
  • Table 7 2: China - Non-CD19 Directed CAR-T Cells Clinical Trials, 2017
  • Table 7 3: China - Solid Tumors CAR-T Cells Clinical Trials, 2017
  • Table 10 1: Global - Venture Capital Investments (Million US$) in CAR-T Cell Therapy, 2011 - 2017
  • Table 10 2: Global - Initial Public Offerings (Million US$) in CAR-T Cell Therapy, 2011 - 2016
  • Table 10 3: Global - CAR-T Companies Strategic Partnerships/Acquisitions, 2012-2017
  • Table 10 4: Global - Key CAR-T Technology Deals, 2012-2017